Relay Therapeutics Inc

+0.28 (+1.35%)
Products, Regulatory

Relay Therapeutics Discloses Anticipated Registrational Path For Rly-4008 In Cholangiocarcinoma And Growing Breast Cancer Franchise At Virtual Analyst And Investor Event

Published: 06/27/2022 10:48 GMT
Relay Therapeutics Inc (RLAY) - Relay Therapeutics Discloses Anticipated Registrational Path for Rly-4008 in Cholangiocarcinoma and Growing Breast Cancer Franchise at Virtual Analyst and Investor Event.
Relay Therapeutics Inc - Discloses Three New Programs As Part of a Growing Hr+/her2- Breast Cancer Franchise.
Relay Therapeutics - Expect Its Current Cash, Cash Equivalents and Investments Will Be Sufficient to Fund Its Current Operating Plan Into 2025.
Relay Therapeutics - End-of-phase 1 Meeting With U.S. FDA Resulted in Alignment on Design of Single Arm Trial for Pan-fgfr Treatment-naÏve Fgfr2-fusion Cholangiocarcinoma.
Relay Therapeutics - Decided to Move Forward With Single Arm Trial Design for Fgfri-naÏve Fgfr2-fusion Cca at 70 Mg Once Daily to Support Accelerated Approval.
Relay Therapeutics Inc - Also Intends to Add Additional Supportive Cca Cohorts to an NDA Submission.
Relay Therapeutics - Entirety of Dose Escalation Data is Expected to Be Presented at a Medical Meeting Or Published by End of First Half of 2023.
Relay Therapeutics Inc - Initial Data From Non-cca Expansion Cohorts is Expected to Be Presented in 2023.